Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients

Pharmacogenomics

Volumn 7, Issue 7, 2006, Pages 987-993

  Xing, Qinghe ^a,b   Gao, Rui ^a,b   Li, Huafang ^c   Feng, Guoyin ^c   Xu, Mingqing ^a,b   Duan, Shiwei ^a,b   Meng, Junwei ^a,b   Zhang, Aiping ^a,b   Qin, Shengying ^a,b   He, Lin ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

^c SHANGHAI MENTAL HEALTH CENTER   (China)

Author keywords

ABCB1; Polymorphism; Response; Risperidone

Indexed keywords

GLYCOPROTEIN P; MEMBRANE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PALIPERIDONE; RISPERIDONE; UNCLASSIFIED DRUG;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CHINESE; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; PATIENT MONITORING; PREDICTION; SCHIZOPHRENIA; SCORING SYSTEM;

ADULT; ANTIPSYCHOTIC AGENTS; CHINA; FEMALE; GENE FREQUENCY; HUMANS; ISOXAZOLES; LINKAGE DISEQUILIBRIUM; MALE; ORGANIC ANION TRANSPORTERS; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; PSYCHIATRIC STATUS RATING SCALES; PYRIMIDINES; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 33750454081     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.7.7.987     Document Type: Article

References (32)

1. Kim RB, Fromm MF, Wandel C et al.: The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 101, 289-294 (1998).
2. Uhr M, Grauer MT: abcb lab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice. J. Psychiatr. Res. 37, 179-185 (2003).
3. Wang JS, Taylor R, Run Y, Donovan LJ, Markowitz SJ, DeVane CL: Olanzapine penetration into brain is greater in transgenic mdr1a P-glycoprotein deficient mice than FVB1 (wild-type) animals. Neuropsychopharmacology 29, 551-557 (2004).
4. Wang JS, DeVane CL, Gibson BB, Donovan JL, Markowitz JS, Zhu HJ: Population pharmacokinetic analysis of drug-drug interactions among risperidone, bupropion, and sertraline in CF1 mice. Psychopharmacology (Berl) 183(4), 490-499 (2006).
5. Yasui-Furukori N, Saito M, Nakagami T, Kaneda A, Tateishi T, Kaneko S: Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients: a preliminary study. Prog. Neuropsychopharmacol. Biol. Psychiatry 30(2), 286-291 (2006).
6. Peuskens J: Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br. J. Psychiatry 166(6), 712-726 (1995).
7. Heck AH, Haffmans PM, de Groot IW, Hoencamp E: Risperidone versus haloperidol in psychotic patients with disturbing neuroleptic-induced extrapyramidal symptoms: a double-blind, multi-center trial. Schizophr. Res. 46(2-3), 97-105 (2000).
8. Csernansky JG, Mahmoud R, Brenner R; Risperidone-USA-79 Study Group: A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N. Engl. J. Med. 346(1), 16-22 (2002).
9. Freudenreich O, Goff DC: Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatr. Scand. 106 (5), 323-330 (2002).
10. Boulton DW, DeVane CL, Liston HL, Markowitz JS: In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci. 71(2), 163-169 (2002).
11. Ejsing TB, Pedersen AD, Linnet K: P-glycoprotein interaction with risperidone and 9-OH-risperidone studied in vitro, in knock-out mice and in drug-drug interaction experiments. Hum. Psychopharmacol. 20(7), 493-500 (2005).
12. Wang JS, Ruan Y, Taylor RM, Donovan JL, Markowitz JS, DeVane CL: The brain entry of risperidone and 9-OH-risperidone is greatly limited by P-glycoprotein. Int. J. Neuropsychopharmacol. 7(4), 415-419 (2004).
13. Fojo A, Lebo R, Shimizu N et al.: Localization of multidrug resistance-associated DNA sequences to human chromosome 7. Somat. Cell. Mol. Genet. 12(4), 415-420 (1986).
14. Hoffmeyer S, Burk O, von Richter O et al.: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl Acad. Sci. USA 97(7), 3473-3478 (2000).
15. Kerb R, Hoffmeyer S, Brinkman U: ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2. Pharmacogenomics 2(1), 51-64 (2001).
16. Furuno T, Landi MT, Ceroni M et al.: Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease. Pharmacogenetics 12(7), 529-534 (2002).
17. Wang D, Johnson AD, Papp AC, Kroetz DL, Sadee W: Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet. Genomics. 15(10), 693-704 (2005).
18. Drozdzik M, Bialecka M, Mysliwiec K, Honczarenko K, Stankiewicz J, Sych Z: Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease. Pharmacogenetics 13(5), 259-263 (2003).
19. Jones PM, George AM: A new structural model for P-glycoprotein. J. Membr. Biol. 166(2), 133-147 (1998).
20. Kim RB, Leake BF, Choo EF et al.: Identification of functionally variant MDR1 alleles among European-Americans and African-Americans. Clin. Pharmacol. Ther. 70(2), 189-199 (2001).
21. Tanabe M, Ieiri I, Nagata N et al.: Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J. Pharmacol. Exp. Ther. 297(3), 1137-1143 (2001).
22. Morita Y, Sakaeda T, Horinouchi M et al.: MDR1 genotype-related duodenal absorption rate of digoxin in healthy Japanese subjects. Pharm. Res. 20(4), 552-556 (2003).
23. Verstuyft C, Schwab M, Schaeffeler E et al.: Digoxin pharmacokinetics and MDR1 genetic polymorphisms. Eur. J. Clin. Pharmacol. 58 (12), 809-12 (2003).
24. Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin. Pharmacol. Ther. 75(1), 13-33 (2004).
25. Llerena A, Berecz R, Dorado P et al.: Determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography: application to the evaluation of CYP2D6 drug interactions. J. Chromatogr. B783, 213-219 (2003).
26. Shi YY, He L: SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res. 15(2), 97-98 (2005).
27. Fanous AH, van den Oord EJ, Riley BP et al.: Relationship between a high-risk haplotype in the DTNBP1 (dysbindin) gene and clinical features of schizophrenia. Am. J. Psychiatry 162(10), 1824-1832 (2005).
28. Hitzl M, Drescher S, van der Kuip H et al.: The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics 11(4), 293-298 (2001).
29. Siegmund W, Ludwig K, Giessmann T et al.: The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin. Pharmacol. Ther. 72 (5), 572-583 (2002).
30. Kimchi-Sarfaty C, Gribar JJ, Gottesman MM: Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system. Mol. Pharmacol. 62(1), 1-6 (2002).
31. Morita N, Yasumori T, Nakayama K: Human MDR1 polymorphism: G2677T/A and C3435T have no effect on MDR1 transport activities. Biochem. Pharmacol. 65(11), 1843-1152 (2003).
32. Sakaeda T, Nakamura T, Horinouchi M et al.: MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm. Res. 18(10), 400-404 (2001).